Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience
Alexis Caulier
(1)
,
Murielle Roussel
(2)
,
Pierre Morel
(1)
,
Naelle Lombion
,
Benoit Branco
,
Jean Galtier
(3)
,
Cyrille Hulin
(3)
,
Aurore Perrot
(4)
,
Valentine Richez
(5)
,
Anne-Victoire Michaud
(6)
,
Cyrille Touzeau
(7, 8, 9, 10)
,
Chantal Doyen
,
Clara Mariette
(11)
,
Denis Caillot
(12)
,
Stephanie Harel
(13)
,
Pascal Lenain
(14)
,
Sarah Ivanoff
(15)
,
Jean Fontan
(16)
,
Anne-Marie Stoppa
(17)
,
Salomon Manier
(18)
,
Laurent Garderet
(19)
,
Xavier Leleu
(20)
,
Jean-Pierre Marolleau
(1, 21)
,
Bertrand Arnulf
(22)
,
Herve Avet-Loiseau
(4)
,
Bruno Royer
(1)
1
CHU Amiens-Picardie
2 CHU Limoges
3 CHU Bordeaux [Bordeaux]
4 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
5 Service hématologie Nice
6 Département de Médecine Nucléaire [CHU Nantes]
7 CRCINA-ÉQUIPE 10 - Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma
8 Service d'Hématologie [Nantes]
9 SIRIC - Site de Recherche Intégrée sur le Cancer [Nantes]
10 ILIAD - Imaging and Longitudinal Investigations to Ameliorate Decision-making [Nantes]
11 CHU - Centre Hospitalier Universitaire [Grenoble]
12 CHU Dijon
13 Service d'Immunopathologie [Hôpital Saint-Louis, Paris]
14 CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
15 Pathologie cellulaire : aspects moléculaires et viraux / Pathologie et Virologie Moléculaire
16 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
17 Service d’Hématologie [Institut Paoli Calmettes, Marseille]
18 CHRU Lille - Centre Hospitalier Régional Universitaire [Lille]
19 CHU Saint-Antoine [AP-HP]
20 CHU Poitiers - Centre hospitalier universitaire de Poitiers
21 HEMATIM - HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666
22 AP-HP - Hopital Saint-Louis [AP-HP]
2 CHU Limoges
3 CHU Bordeaux [Bordeaux]
4 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
5 Service hématologie Nice
6 Département de Médecine Nucléaire [CHU Nantes]
7 CRCINA-ÉQUIPE 10 - Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma
8 Service d'Hématologie [Nantes]
9 SIRIC - Site de Recherche Intégrée sur le Cancer [Nantes]
10 ILIAD - Imaging and Longitudinal Investigations to Ameliorate Decision-making [Nantes]
11 CHU - Centre Hospitalier Universitaire [Grenoble]
12 CHU Dijon
13 Service d'Immunopathologie [Hôpital Saint-Louis, Paris]
14 CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
15 Pathologie cellulaire : aspects moléculaires et viraux / Pathologie et Virologie Moléculaire
16 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
17 Service d’Hématologie [Institut Paoli Calmettes, Marseille]
18 CHRU Lille - Centre Hospitalier Régional Universitaire [Lille]
19 CHU Saint-Antoine [AP-HP]
20 CHU Poitiers - Centre hospitalier universitaire de Poitiers
21 HEMATIM - HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666
22 AP-HP - Hopital Saint-Louis [AP-HP]
Naelle Lombion
- Fonction : Auteur
Benoit Branco
- Fonction : Auteur
Aurore Perrot
- Fonction : Auteur
- PersonId : 769019
- IdRef : 139420215
Cyrille Touzeau
- Fonction : Auteur
- PersonId : 778761
- ORCID : 0000-0003-0275-2575
Chantal Doyen
- Fonction : Auteur
Laurent Garderet
- Fonction : Auteur
- PersonId : 761986
- ORCID : 0000-0002-6138-8112
Jean-Pierre Marolleau
- Fonction : Auteur
- PersonId : 887235
- IdRef : 06981676X
Herve Avet-Loiseau
- Fonction : Auteur
- PersonId : 948224
- ORCID : 0000-0002-3050-0140
Résumé
Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing <2% of all patients with MM. Little is known about the disease characteristics and prognosis of these patients. In this study, we examined 214 patients diagnosed with MM at age <= 40 years over 15 years, in the era of modern treatments. Among them, 189 patients had symptomatic MM. Disease characteristics were similar to older patients: 35% had anemia, 17% had renal impairment, and 13% had hypercalcemia. The staging was ISS-1 in 52.4%, ISS-2 in 27.5%, and ISS-3 in 20.1%. Overall, 18% of patients had high-risk cytogenetics [del 17p and/or t(4;14)]. Ninety percent of patients received intensive chemotherapy followed by autologous stem cell transplant, and 25% of patients had allogeneic stem cell transplant predominantly at time of relapse. The median follow-up was 76 months, the estimated median overall survival was 14.5 years, and the median progression free-survival was 41 months. In multivariate analysis, bone lesions (hazard ratio [HR], 3.95; P =.01), high ISS score (HR, 2.14; P =.03), and high-risk cytogenetics (HR, 4.54; P <.0001) were significant risk factors for poor outcomes. Among predefined time-dependent covariables, onset of progression (HR, 13.2; P <.0001) significantly shortened overall survival. At 5 years, relative survival compared with same age- and sexmatched individuals was 83.5%, and estimated standardized mortality ratio was 69.9 (95% confidence interval, 52.7-91.1), confirming that MM dramatically shortens the survival of young patients despite an extended survival after diagnosis.